Combined antiparasitic treatment for neurocysticercosis - Authors' reply

dc.date.accessioned2019-02-06T14:59:07Z
dc.date.available2019-02-06T14:59:07Z
dc.date.created2019-02-06T14:59:07Z
dc.date.issued2015
dc.identifierhttps://hdl.handle.net/20.500.12866/5556
dc.identifierhttps://doi.org/10.1016/S1473-3099(15)70047-2
dc.description.abstractWe thank Aba Mahamat and colleagues for their comments on our Article1 and patient data illustrating a difficult case successfully treated with combined albendazole and praziquantel. We do not deem use of the combination a “shift”, rather a refinement in use of antiparasitic treatment to destroy viable brain parasites, which has been in use for more than 25 years. We certainly agree that antiparasitic treatment in neurocysticercosis should be individualised and not used as a blanket recipe...
dc.languageeng
dc.publisherElsevier
dc.relationLancet. Infectious Diseases
dc.relation1474-4457
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectAnthelmintics/therapeutic use
dc.subjectAlbendazole/therapeutic use
dc.subjectNeurocysticercosis/drug therapy
dc.subjectPraziquantel/therapeutic use
dc.titleCombined antiparasitic treatment for neurocysticercosis - Authors' reply
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución